1. Home
  2. ZURA vs KOP Comparison

ZURA vs KOP Comparison

Compare ZURA & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZURA
  • KOP
  • Stock Information
  • Founded
  • ZURA 2022
  • KOP 1988
  • Country
  • ZURA United States
  • KOP United States
  • Employees
  • ZURA N/A
  • KOP N/A
  • Industry
  • ZURA Biotechnology: Biological Products (No Diagnostic Substances)
  • KOP Forest Products
  • Sector
  • ZURA Health Care
  • KOP Basic Materials
  • Exchange
  • ZURA Nasdaq
  • KOP Nasdaq
  • Market Cap
  • ZURA 69.9M
  • KOP 674.1M
  • IPO Year
  • ZURA N/A
  • KOP 2006
  • Fundamental
  • Price
  • ZURA $1.30
  • KOP $33.75
  • Analyst Decision
  • ZURA Buy
  • KOP Buy
  • Analyst Count
  • ZURA 7
  • KOP 1
  • Target Price
  • ZURA $14.33
  • KOP $64.00
  • AVG Volume (30 Days)
  • ZURA 712.2K
  • KOP 127.6K
  • Earning Date
  • ZURA 08-08-2025
  • KOP 08-07-2025
  • Dividend Yield
  • ZURA N/A
  • KOP 0.95%
  • EPS Growth
  • ZURA N/A
  • KOP N/A
  • EPS
  • ZURA N/A
  • KOP 1.22
  • Revenue
  • ZURA N/A
  • KOP $2,051,000,000.00
  • Revenue This Year
  • ZURA N/A
  • KOP N/A
  • Revenue Next Year
  • ZURA N/A
  • KOP $2.61
  • P/E Ratio
  • ZURA N/A
  • KOP $27.47
  • Revenue Growth
  • ZURA N/A
  • KOP N/A
  • 52 Week Low
  • ZURA $0.97
  • KOP $22.99
  • 52 Week High
  • ZURA $5.07
  • KOP $41.64
  • Technical
  • Relative Strength Index (RSI)
  • ZURA 58.73
  • KOP 59.98
  • Support Level
  • ZURA $1.00
  • KOP $32.92
  • Resistance Level
  • ZURA $1.45
  • KOP $35.61
  • Average True Range (ATR)
  • ZURA 0.10
  • KOP 1.05
  • MACD
  • ZURA 0.03
  • KOP 0.09
  • Stochastic Oscillator
  • ZURA 66.67
  • KOP 65.50

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

Share on Social Networks: